Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
45
PALI Quote, Financials, Valuation and Earnings
Last price:
$1.99
Seasonality move
:
-0.03%
Day range:
$1.86 - $2.03
52-week range:
$0.53 - $2.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
88.31x
Volume:
4.5M
Avg. volume:
5.7M
1-year change:
-1%
Market cap:
$283.5M
Revenue:
--
EPS (TTM):
-$4.22
Analysts' Opinion
-
Consensus RatingPalisade Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $15.00, Palisade Bio, Inc. has an estimated upside of 689.47% from its current price of $1.99.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing -215.79% downside risk from its current price of $1.99.
Fair Value
-
According to the consensus of 2 analysts, Palisade Bio, Inc. has 689.47% upside to fair value with a price target of $15.00 per share.
PALI vs. S&P 500
-
Over the past 5 trading days, Palisade Bio, Inc. has underperformed the S&P 500 by -19.89% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Palisade Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Palisade Bio, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Palisade Bio, Inc. reported revenues of --.
Earnings Growth
-
Palisade Bio, Inc. has grown year-over-year earnings for 11 quarters straight. In the most recent quarter Palisade Bio, Inc. reported earnings per share of -$0.38.
Enterprise value:
278.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-27.62x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3K
Return On Assets:
-133.5%
Net Income Margin (TTM):
--
Return On Equity:
-222.18%
Return On Invested Capital:
-212.65%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $250K | -- | -- | -- | -- | |
| Gross Profit | $170K | -$3K | -$3K | -$1K | -$1K | |
| Operating Income | -$13.4M | -$14.8M | -$11.5M | -$3.6M | -$2.9M | |
| EBITDA | -$13.3M | -$14.8M | -$11.5M | -$3.6M | -$2.9M | |
| Diluted EPS | -$43.86 | -$15.04 | -$4.22 | -$2.32 | -$0.38 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $16.1M | $15.1M | $16.2M | $8.8M | $6.2M | |
| Total Assets | $16.3M | $16.3M | $17.1M | $9.3M | $7M | |
| Current Liabilities | $2.9M | $3.5M | $2.6M | $2.7M | $3.5M | |
| Total Liabilities | $12.4M | $3.8M | $3M | $2.7M | $3.8M | |
| Total Equity | $3.9M | $12.4M | $14.1M | $6.6M | $3.2M | |
| Total Debt | $568K | $591K | $381K | $235K | $211K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$11.7M | -$12.6M | -$10.1M | -$3.1M | -$3.6M | |
| Cash From Investing | -$14K | -- | -- | -- | -- | |
| Cash From Financing | $13M | $5.3M | $7.3M | -$180K | $3.4M | |
| Free Cash Flow | -$11.7M | -$12.6M | -$10.1M | -$3.1M | -$3.6M | |
PALI
Sector
Market Cap
$283.5M
$28.3M
Price % of 52-Week High
71.97%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
-99.77%
-1.59%
1-Year Price Total Return
-5.47%
-17.41%
Beta (5-Year)
1.432
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.14
200-day SMA
Buy
Level
$1.15
Bollinger Bands (100)
Buy
Level
0.93 - 2.15
Chaikin Money Flow
Sell
Level
-324.4K
20-day SMA
Sell
Level
$2.03
Relative Strength Index (RSI14)
Sell
Level
48.57
ADX Line
Buy
Level
39.24
Williams %R
Neutral
Level
-75.0507
50-day SMA
Sell
Level
$1.99
MACD (12, 26)
Buy
Level
0.48
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
23.3M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-20.3396)
Sell
CA Score
(Annual)
Level (-4.672)
Buy
Beneish M-Score
(Annual)
Level (-5.9494)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (10.91)
Sell
Piotroski F Score
(Annual)
Level (3)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company was founded on September 6, 2011 and is headquartered in Carlsbad, CA.
Stock Forecast FAQ
In the current month, PALI has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PALI average analyst price target in the past 3 months is $15.00.
-
Where Will Palisade Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Palisade Bio, Inc. share price will rise to $15.00 per share over the next 12 months.
-
What Do Analysts Say About Palisade Bio, Inc.?
Analysts are divided on their view about Palisade Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Palisade Bio, Inc. is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Palisade Bio, Inc.'s Price Target?
The price target for Palisade Bio, Inc. over the next 1-year time period is forecast to be $15.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PALI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Palisade Bio, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PALI?
You can purchase shares of Palisade Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Palisade Bio, Inc. shares.
-
What Is The Palisade Bio, Inc. Share Price Today?
Palisade Bio, Inc. was last trading at $1.99 per share. This represents the most recent stock quote for Palisade Bio, Inc.. Yesterday, Palisade Bio, Inc. closed at $1.99 per share.
-
How To Buy Palisade Bio, Inc. Stock Online?
In order to purchase Palisade Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get PALI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
PALI
Sector
P/E ratio
--
24.24x
PEG ratio
--
-0.01x
P/B ratio
88.31x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
PALI
Sector
Revenue growth
--
4.6%
Earnings growth
83.49%
10.71%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
-$0.03
-$0.19
Profitability
PALI
Sector
Profitability FY 2024
-$3K
$3.5M
Return on invested capital
-212.65%
-32.04%
Return on assets
-133.5%
-28.44%
Return on equity
-222.18%
-38.09%
Earnings Date
Last Earnings Date
Jan
10
Next Earnings Date
Jan
10
Estimated Next Earnings Date
Apr
11
Balance Sheet
PALI
Sector
Total cash
$5.2M
$26.1M
Short term investments
--
$25.7M
Total assets
$10.9M
$76.4M
Long term debt
$211K
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
